SPECIAL REPORT: How Will the Withdrawal of Generic Albuterol Change the U.S. Respiratory Disease Market?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• The Montreal Protocol
• Respiratory Diseases
  • An Overview of Asthma
    • Disease Defi nition, Etiology, and Prevalence
    • Treatment of Asthma
  • An Overview of Chronic Obstructive Pulmonary Disease
    • Disease Defi nition, Etiology, and Prevalence
    • Treatment of COPD
  • Use of Symptomatic Bronchodilators in the Treatment of Asthma and COPD
• The Respiratory Disease Market
  • Controller Agents
  • Reliever Agents
  • The Albuterol Market in the United States
• Challenges of the Switch to HFA Formulations
  • Demand and Manufacturing Concerns
  • Manufacturer Compliance
  • Lack of Equivalence
  • Reimbursement Issues
• Market Outlook
  • Demand for Albuterol
  • Competitive Threats
  • U.S. Market Forecast
  • Winners and Losers

• Appendix A. Market Forecast Scenarios for Branded HFA Products in the United States, 2006-2011
  • Methodology and Assumptions
    • Drug-Treated Population
    • Treated Days and Compliance
    • Price per Patient per Year
  • Scenario 1: Proventil HFA Takes Early Market Leadership
  • Scenario 2: Competitive Pricing
  • Scenario 3: Physicians Choose to Switch Patients to Xopenex

Tables

• 1. Prevalent Cases of Asthma and COPD, 2006
• 2. Sales of Leading Agents to Treat Asthma and COPD, 2006
• 3. Forecasted Sales of Reliever Agents in the United States, 2008 and 2011
• A. Combined Asthma and COPD Drug-Treated Populations in the United States, 2006-2011
• B. Annual Cost of HFA Agents for a Single Patient

Figures

• 1. Sales of Albuterol, 1986 - 2006
• 2. Sales of Albuterol in the United States, 2000-2006
• A. Sales of Short-Acting Beta2 Agonists (Scenario 1: Proventil Takes Early Market Leadership), 2006-2011
• B. U.S. Market Shares, 2011 (Scenario 1: Proventil Takes Early Market Leadership)
• C. Sales of Short-Acting Beta2 Agonists (Scenario 2: Competitive Pricing), 2006-2011
• D. U.S. Market Shares, 2011 (Scenario 2: Competitive Pricing)
• E. Sales of Short-Acting Beta2 Agonists (Scenario 3: Physicians Switch Patients to Xopenex), 2006-2011
• F. U.S. Market Shares, 2011 (Scenario 3: Physicians Switch Patients to Xopenex)

Sidebars

• Barriers to Entry:What Is Discouraging Companies from Developing Albuterol?
• How Will Albuterol Manufacturers Differentiate Their Products?